Back | Next |
home / stock / reta / reta message board
Subject | By | Source | When |
---|---|---|---|
Boing | Awl416 | investorshub | 02/28/2023 10:56:42 PM |
Ticking higher. $30 puts should expire worthless. | IPO$ | investorshub | 02/28/2023 7:45:17 PM |
The $20 puts have a lot of premium | IPO$ | investorshub | 02/28/2023 6:30:36 PM |
There appeared to be securities fraud today with | IPO$ | investorshub | 02/27/2023 10:53:25 PM |
I heard. That should have no direct effect | IPO$ | investorshub | 02/27/2023 8:54:05 PM |
Apparently it is because they were expecting FDA | rynlrt | investorshub | 02/27/2023 6:26:46 PM |
Just bot at 30. Hope I want it. | MiamiGent | investorshub | 02/27/2023 5:01:34 PM |
How could a stock dropped 30% and there | IPO$ | investorshub | 02/27/2023 4:37:04 PM |
Up today! | IPO$ | investorshub | 02/27/2023 2:42:28 PM |
Up pre mkt | IPO$ | investorshub | 02/27/2023 2:13:09 PM |
Moved cash into mkt debt securities. US TBills | IPO$ | investorshub | 02/24/2023 2:33:07 PM |
Cash shrank in q4 | IPO$ | investorshub | 02/24/2023 2:32:08 PM |
Emphasis of a matter in EY audit opinion. | IPO$ | investorshub | 02/24/2023 2:17:46 PM |
10-k issued. | IPO$ | investorshub | 02/24/2023 2:12:51 PM |
Up strong today. | IPO$ | investorshub | 02/22/2023 7:02:01 PM |
Will co get FDA approval on 2/28/2023? | IPO$ | investorshub | 02/22/2023 7:01:24 PM |
znewcar1: RETA 21% v5,3M c27.07 f36,5M H27.82 Haft28.97 ML18.47 | znewcar1 | investorshangout | 09/08/2022 12:37:50 AM |
znewcar1: RETA 25% v2,9M c32.74 f36,4M H32.9 S22.7 | znewcar1 | investorshangout | 02/28/2022 11:46:42 PM |
What am I missing????? | JayFlinty | investorshub | 12/10/2021 4:46:45 PM |
znewcar1: RETA 23% v2,7M c102.63 f36,2M H103 | znewcar1 | investorshangout | 05/20/2021 3:08:46 AM |
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...